The prevalence of viral hepatitis D in the world
https://doi.org/10.31631/2073-3046-2022-21-3-90-95
Abstract
Relevance According to many researchers, hepatitis D worsens the prognosis of hepatitis B in 80–90% of cases, accelerating fibrosis and leading to liver cirrhosis or hepatocellular carcinoma. Aims. To present a review of data on prevalence of hepatitis D in the Russian Federation and abroad. Conclusions. Hepatitis D is most common in such regions of the world as: Africa, South America, Middle East, North Asia and in some Mediterranean countries. Conclusions. Injecting drug users play a large role among vulnerable populations. Hepatitis B vaccination limits the spread of hepatitis D.
About the Authors
V. G. Akimkin
Central Research Institute of Epidemiology, Federal Service on Customers Rights Protection Human Well-being Surveillance
Russian Federation
Russian Federation
Vasily G. Akimkin – Academician of the Russian Academy of Sciences, Dr. Sci. (Med.), Professor, Director Central Research Institute of Epidemiology
3a, ul. Novogireevskaya, Moscow, 111123
+7 (903) 013-09-74
Z. B. Ponezheva
Central Research Institute of Epidemiology, Federal Service on Customers Rights Protection Human Well-being Surveillance
Russian Federation
Russian Federation
Zhanna B. Ponezheva – Dr. Sci. (Med.), Head of the clinical department of infectious pathology
3a, ul. Novogireevskaya, Moscow, 111123
+7 (903) 145-50-07
Kh. G. Omarova
Central Research Institute of Epidemiology, Federal Service on Customers Rights Protection Human Well-being Surveillance
Russian Federation
Russian Federation
Khadizhat G. Omarova – Cand. Sci. (Med.), Senior researcher of the Central Research Institute of Epidemiology
3a, ul. Novogireevskaya, Moscow, 111123
+7 (926) 286-42-66
Yu. А. Goloverova
Central Research Institute of Epidemiology, Federal Service on Customers Rights Protection Human Well-being Surveillance
Russian Federation
Russian Federation
Yuliya A. Goloverova – laboratory-researcher laboratory of healthcare-associated infections Central Research Institute of Epidemiology
3a, ul. Novogireevskaya, Moscow, 111123
+7 (901) 332-46-57
S. V. Ugleva
Central Research Institute of Epidemiology, Federal Service on Customers Rights Protection Human Well-being Surveillance
Russian Federation
Russian Federation
Svetlana V. Ugleva – Dr. Sci. (Med.), Assoc. Prof., consultant, Organizational and methodological department, Administrative division, Central Research Institute of Epidemiology
3a, ul. Novogireevskaya, Moscow, 111123
+7 (905) 360-87-77
S. V. Shabalina
Central Research Institute of Epidemiology, Federal Service on Customers Rights Protection Human Well-being Surveillance
Russian Federation
Russian Federation
Svetlana V. Shabalina – Dr. Sci. (Med.), Professor, Leading researcher clinical department of infectious pathology Central Research Institute of Epidemiology
3a, ul. Novogireevskaya, Moscow, 111123
+7 (906) 743-48-64
References
1. Lerut J.P., Donataccio M., Ciccarelli O., et al. Liver transplantation and HBsAg-positive postnecrotic cirrhosis: adequate immunoprophylaxis and delta virus co-infection as the significant determinants of long-term prognosis. J Hepatol. 1999. Vol. 30, № 4. P. 706–714. doi: 10.1016/s0168-8278(99)80203-7
2. Isaeva O.V., Kuregyan K.K. Viral hepatitis delta: an underestimated threat. Infektsionnye bolezni: novosti, mneniya, obuchenie. Infectious Diseases: News, Opinions, Training. 2019;8(2):72–79 (In Russ). doi: 10.24411/2305-3496-2019-12010
3. Miao Z, Zhang S, Ou X, et al. Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection. J Infect Dis. 2020 Apr 27;221(10):1677–1687. doi: 10.1093/infdis/jiz633.
4. Chen H.Y., Shen D.T., Ji D.Z., et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis Gut. 2019. Vol. 68, № 3. P. 512–521. doi: 10.1136/gutjnl-2018-316601
5. Vlachogiannakos J, Papatheodoridis GV. New epidemiology of hepatitis delta. Liver Int. 2020. Vol. 40, Suppl. P. 148–153. doi: 10.1111/liv.14357
6. Sleptsova S.S., Malov S.I. Savilov E.D., et al. Clinical and Epidemiological Characteristics of Hepatocellular Carcinoma in the Republic of Saha (Yakutia). Epidemiology and Vaccinal Prevention. 2020;19(3):33–40 (In Russ.). doi: 10.31631/2073-30462020-19-3-33-40
7. Romeo R., Perbellini R. Hepatitis delta virus: Making the point from virus isolation up to 2014. World J Hepatol. 2015. Vol. 7, № 22. P. 2389–2395. doi: 10.4254/wjh.v7.i22.2389
8. Bissinger A.L., Fehrle C., Werner C.R., et al. Epidemiology and Genotyping of Patients with Chronic Hepatitis B: Genotype Shifting Observed in Patients from Central Europe. Pol J Microbiol. 2015. Vol. 64, № 1. P. 15–21.
9. Semenov A.V., Ostankova Yu.V., Nogoybaeva K.A., et al. Molecular epidemiology features of HBV/ВГD co-infection in Kyrgyzstan Russian Journal of Infection and Immunity = Infektsiya i immunitet. 2016. Vol. 6, № 2. P. 141–150 (In Russ). doi: 10.15789/2220-7619-2016-2-141-150
10. Casey J.L., Niro G.A., Engle R.E., et al. Hepatitis B virus (ВГD) coinfection in outbreaks of acute hepatitis in the Peruvian Amazon basin: the roles of ВГD genotype F. J Infect Dis. 1996. Vol. 174, № 5. P. 920–926. doi: 10.1093/infdis/174.5.920.
11. Su C.W., Huang Y.H., Huo T.I., et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients Gastroenterology. 2006;130(6):1625–1635. doi: 10.1053/j.gastro.2006.01.035/
12. Ott J.J., Stevens G.A., Groeger J., et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity Vaccine. 2012. Vol. 30, № 12. P. 2212–2219. doi: 10.1016/j.vaccine.2011.12.116
13. Isaeva O.V., Ilchenko L.Yu., Kozhanova T.V., et al. The impact of universal vaccination against hepatitis B on the prevalence of hepatitis D in endemic region Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2019. Vol. 8. № 2. P. 36–42 (In Russ). doi: 10.24411/2305-3496-2019-12004
14. Sellier P.O., Maylin S., Brichler S., et al. Hepatitis B Virus-Hepatitis D Virus mother-to-child co-transmission: A retrospective study in a developed country. Liver Int. 2018. Vol. 38, № 4. P. 611–618. doi: 10.1111/liv.13556
15. Fact sheets WHO. Hepatitis D. Available: https:www.who.int/ru/news-room/fact-sheets/detail/hepatitis-d. Accessed: 30 Apr 2020.
16. Syutkin V.E., Salienko A.A. Hepatitis D. The present state of the problem and unsolved problems Epidemiology and infectious diseases. Current items. 2013. Vol.4. P. 45–49 (In Russ).
17. Levitan B.N., Dedov А.V. Hepatitis Delta – 2019. Part I: the Aetiology, Epidemiology, Features of the Clinical Course and Outcomes. Effective pharmacotherapy. 2019. Vol. 15, № 18. P. 42–50 (In Russ). doi: 10/33978/2307-3586-2019-15-18-42-50.
18. Chen H.Y., Shen D.T., Ji D.Z., et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2019. Vol. 68, № 3. P. 512–521. doi: 10.1136/gutjnl-2018-316601
19. Scarponi C.F.O., Silva R.D.N.D., Souza Filho J.A., et al. Hepatitis Delta Prevalence in South America: A Systematic Review and Meta-Analysis. Rev Soc Bras Med Trop. 2019, Vol. 52. P. e20180289. doi: 10.1590/0037-8682-0289-2018
20. Stockdale A.J., Chaponda M., Beloukas A., et al. Prevalence of hepatitis D virus infection in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Glob Health. 2017. Vol. 5, № 11. P. e992–e1003. doi: 10.1016/S2214-109X(17)30298-X
21. Gaeta G.B., Stroffolini T., Chiaramonte M., et al. Chronic hepatitis D: a vanishing Disease? An Italian multicenter study Hepatology. 2000. Vol. 32, № 4. Pt 1. P. 824–827. doi: 10.1053/jhep.2000.17711
22. Ordieres C., Navascués C.A., González-Diéguez M.L., et al. Prevalence and epidemiology of hepatitis D among patients with chronic hepatitis B virus infection: a report from Northern Spain. Eur J Gastroenterol Hepatol. 2017. Vol. 29, № 3. P. 277–283. doi: 10.1097/MEG.0000000000000795
23. Değertekin H., Yalçin K., Yakut M., et al. Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int. 2008. Vol. 28, № 4. P. 494–498. doi: 10.1111/j.1478-3231.2008.01673.x
24. Manesis E.K., Vourli G., Dalekos G., et al. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. J Hepatol. 2013. Vol. 59, № 5. P. 949–956. doi: 10.1016/j.jhep.2013.07.005
25. Sagnelli E., Stroffolini T., Mele A., et al. Chronic hepatitis B in Italy: new features of an old disease-approaching the universal prevalence of hepatitis B e antigen-negative cases and the eradication of hepatitis D infection. Clin Infect Dis. 2008. Vol. 46, № 1. P. 110–113. doi: 10.1086/524074
26. Stroffolini T. The changing pattern of hepatitis B virus infection over the past three decades in Italy. Dig Liver Dis. 2005. Vol. 37, № 8. P. 622–627. doi: 10.1016/j.dld.2005.02.010
27. Zarski J.P., Marcellin P., Leroy V., et al. Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. J Hepatol. 2006. Vol. 45, № 3. P. 355–360. doi:10.1016/j.jhep.2006.03.007
28. Mele A., Mariano A., Tosti M.E., et al. Acute hepatitis delta virus infection in Italy: incidence and risk factors after the introduction of the universal anti-hepatitis B vaccination campaign. Clin Infect Dis. 2007. Vol. 44, № 3. P. e17–24. doi: 10.1086/510433
29. Cross T.J., Rizzi P., Horner M., et al. The increasing prevalence of hepatitis delta virus (ВГD) infection in South London. J Med Virol. 2008. Vol. 80, № 2. P. 277–282. doi: 10.1002/jmv.21078
30. Safaie P., Razeghi S., Rouster S.D., et al. Hepatitis D diagnostics:Utilization and testing in the United States. Virus Res. 2018. Vol. 250. P. 114–117. doi: 10.1016/j.virusres.2018.03.013.
31. Fattovich G., Giustina G., Christensen E., et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep) Gut. Vol. 46, № 3. P. 420–426. doi: 10.1136/gut.46.3.420
32. Gish R.G., Gadano A.C. Chronic hepatitis B: current epidemiology in the Americas and implications for management. J Viral Hepat. 2006. Vol. 13, № 12. P. 787–798. doi: 10.1111/j.1365-2893.2006.00787.x
33. Soriano V., Sherman K.E, Barreiro P. Hepatitis delta and HIV infection. AIDS. 2017. Vol. 31, № 7. P. 875–884. doi: 10.1097/QAD.0000000000001424
34. Kushner T., Serper M., Kaplan D.E. Delta hepatitis within the Veterans Affairs medical system in the United States: Prevalence, risk factors, and outcomes. J Hepatol. 2015. Vol. 63, № 3. P. 586–592. doi: 10.1016/j.jhep.2015.04.025
35. Gish R.G., Yi D.H., Kane S., et al. Coinfection with hepatitis B and D: epidemiology, prevalence and disease in patients in Northern California. J Gastroenterol Hepatol. 2013. Vol. 28, № 9. P.1521–1525. doi: 10.1111/jgh.12217
36. Khodjaeva M., Ibadullaeva N., Khikmatullaeva A., et al. The medical impact of hepatitis D virus infection in Uzbekistan Liver Int. 2019. Vol. 39, № 11. P. 2077–2081. doi: 10.1111/liv.14243.
37. Frolov M.Yu., Rogov V.A., Salasyuk A.S., et al. Clinical and economic aspects of bulevirtide use in patients with chronic hepatitis D. Infekc. bolezni (Infectious diseases). 2020. Vol. 18, № 2. P. 104–111 (In Russ). doi: 10.20953/1729-9225-2020-2-104-111
38. Mentha N., Clement S., Negro F., et al. A review on hepatitis D: From virology to new therapies. Journal of Advanced Research. 2019. Vol. 17. P. 3–15. doi: 10.1016/j.jare.2019.03.009
39. Da B.L., Heller T., Koh C. Hepatitis D infection: from initial discovery to current investigational therapies. Gastroenterol Rep (Oxt). 2019. Vol. 7, № 4. P. 231–245. doi: 10.1093/gastro/goz023.
40. Asselah T., Loureiro D., Tout I., et al. Future treatments for hepatitis delta virus infection. Liver Int. 2020. Vol. 40, № Suppl 1. P. 54–60. doi:10.1111/liv.14356
41. Levitan B.N., Dedov А.V. Hepatitis Delta – 2019. Part II: Modern Treatment and Its Promise Effective pharmacotherapy. 2019. Vol. 15, № 28. С. 76–82 (In Russ). doi: 10.33978/2307-3586-2019-15-28-76-82
42. Gilman C., Heller T., Koh C. Chronic hepatitis delta: A state-of-the-art review and new therapies. Word J Gastroenterol. 2019. Vol. 25, № 32. P. 4580–4597. doi: 10.3748/wjg.v25.i32.4580
43. Hercun J., Koh C., Heller T. Hepatitis Delta: Prevalence, Natural History, and Treatments Options. Gastroenterol Clin North Am. 2020. Vol. 49. № 2. P. 239–252. doi: 10/1016/j.gtc.2020.01.004/
44. Yurdaydin C., Abbas Z., Buti M., et al. Treating chronic hepatitis delta: The need for surrogate markers of treatments efficacy. J Hepatol. 2019. Vol. 70, № 5. P. 1008–1015. doi: 10.1016/j.jhep.2018.12.022
45.
Review
For citations:
Akimkin V.G., Ponezheva Z.B., Omarova Kh.G., Goloverova Yu.А., Ugleva S.V., Shabalina S.V. The prevalence of viral hepatitis D in the world. Epidemiology and Vaccinal Prevention. 2022;21(3):90-95. (In Russ.) https://doi.org/10.31631/2073-3046-2022-21-3-90-95
Views:
609
Email this article 